Rapid advances in genomics are revolutionizing the treatment of patients and providing exciting new opportunities for participants in the life sciences industry. Lawyers at Maynard Cooper provide strategic advice to clients who are at the cutting edge of these developments, including in areas such as personalized medicine, pharmaceuticals, biologics, biosimilars, diagnostics, vaccines, medicinal chemicals, medical devices, and drug delivery systems.
Many of our lawyers have advanced scientific or technical degrees and participated in the development of the science that is at the heart of these new breakthroughs in medical care, including the human genome project and the characterization of chromosome structure and function. The lawyers on our Personalized Medicine team are business and intellectual property strategists who assist clients to protect their groundbreaking discoveries and bring them to market.
Maynard Cooper lawyers have expertise in key areas of law affecting the companies and research institutions that are at the forefront of innovation in this emerging discipline, including corporate formation, intellectual property, regulatory matters including approvals, healthcare, litigation, products liability and class actions.
The protection of intellectual property is a key component of our services in the personalized medicine and genomics arena. We offer clients a full range of intellectual property legal services and advice for their products, from procurement to transactional and litigation matters. With decades of experience as trusted advisors to both start-ups and multinational corporations alike, we understand how patents fit into a company’s overall business model and help clients build their patent portfolios and craft intellectual property strategies that help them achieve their corporate goals.
For example, our lawyers have deep experience representing both generic and branded pharmaceutical and biopharmaceutical companies in matters involving some of their most important drugs. Examples of the small and large molecules that have been the subject of patent actions litigated by our lawyers include high profile pharmaceuticals and biologics such as Oxycodon/Oxycontin, Sildenafil/Viagra, Filgrastim/Neupogen, Tramadol/Ultram, Epinephrine/EpiPen, Pramipexole/Mirapex, Nitrofurantoin/Macrobid, Timolol Maleate/Timoptic, Hepatitis C Protease, Tobramycin/Tobi and Interferon.
At Maynard Cooper, we are client-driven with decades of experience advising both large and small pharmaceutical and biotech companies in all aspects of their businesses, and we are committed to providing excellent service at an uncommon value so that our clients can meet their business objectives in an efficient and cost effective way.
Birmingham, Al. Maynard Cooper & Gale is pleased to announce that Raymond L. Bell, Jr. has joined the Firm as a Shareholder in the Government Solutions Practice Group of the Corporate Section. Bell will practice out of both the Mobile…
On November 20, 2018, Leland Murphree will be on a webinar panelist for the American Bankruptcy Institute, “Hot Issues in the Ongoing Third Party Release Debates.”